Fractional CO₂ laser is widely used in dermatological treatments; however, excessive local inflammatory responses frequently occur following treatment and may contribute to post-treatment complications, highlighting the importance of controlling cutaneous inflammation. Ganoderma lucidum polysaccharides have been reported to possess various pharmacological activities, including anti-inflammatory effects, but their role in laser-induced skin inflammation remains unclear. In this study, a guinea pig model of fractional CO₂ laser-induced skin inflammation was established, and a Ganoderma lucidum polysaccharide fraction (GLP) was topically applied at different concentrations following laser treatment. Histopathological analysis showed reduced inflammatory cell infiltration after GLP treatment, with the greatest reduction observed in the 80 mg/mL group. RNA sequencing revealed that laser-induced differentially expressed genes (DEGs) were enriched in multiple inflammation-related pathways, including cytokine-cytokine receptor interaction, IL-17, TNF, NF-κB, and Jak-STAT signaling pathways. Furthermore, exploratory transcriptomic analysis suggested that GLP treatment was associated with alterations in multiple inflammation-related pathways. In vitro experiments using lipopolysaccharide-stimulated HaCaT cells, fibroblasts, and human umbilical vein endothelial cells showed that GLP reduced the mRNA expression of several inflammation-related factors. Collectively, these findings provide evidence supporting the anti-inflammatory effects of GLP following fractional CO₂ laser treatment. Clinical trial number: Not applicable.
To evaluate the feasibility of Colposcopic Magnified Scanning Laser Treatments (CMSLT), divided into laser excision (CMSLE) and vaporization (CMSLV), using a scanner-assisted CO2 laser as a singular outpatient therapeutic modality for patients affected by vaginal high-grade squamous intraepithelial lesion (vaHSIL). vaginal high-grade squamous intraepithelial lesion (vaHSIL) is a rare condition associated with persistent high-risk HPV infection, carrying a concrete potential for progression into invasive carcinoma. Due to diagnostic complexities and the rarity of the disease, its optimal clinical management and treatment standardization remain controversial. This prospective non-randomized cohort study was conducted between January 2022 and June 2024 on 63 patients with histologically confirmed vaHSIL. Based on the 2011 IFCPC colposcopic terminology, patients were assigned to either the CMSLV group (n = 22) or the CMSLE group (n = 41). The outpatient protocol utilized a laser system implemented with a computerized surgical scanner-assisted micromanipulator. The two-year follow-up included semi-annual screenings with HPV testing, cytology, and colposcopy. Follow-up adherence was high, with a dropout rate limited to 11.3
To investigate the surface modification (changes in roughness, morphology, and chemical composition) of human enamel subjected to multiple Nd:YAG laser irradiations over a photoabsorber, with and without the subsequent application of acidulated phosphate fluoride (APF), in a caries control protocol. 150 enamel blocks (4 × 4 mm) from human third molars were randomly distributed into 10 groups based on surface microhardness: control groups (CN, CF) and irradiated groups subjected to 1, 2, 3, or 4 successive scans. A pulsed Nd:YAG laser (1064 nm, 65 mJ/pulse, 10 Hz, 51.7 J/cm²) irradiated the surfaces using a motorized stage with calculated speed for partial pulse overlap. An aqueous coal powder suspension (equal parts of ultrapure water and 99
Psoriasis remains a therapeutic challenge, demanding safer, more effective, and cost-efficient treatment modalities. This study evaluated the therapeutic potential and underlying mechanisms of Dynamic Permanent Magnetic Field (DPMF) intervention alone and in combination with calcipotriol in an imiquimod (IMQ)-induced mouse model of psoriasis. Sixty-six male BALB/c mice were randomized into seven groups (n = 8–10/group). Following daily IMQ application, intervention groups received either 30-min or 60-min DPMF exposure, topical calcipotriol, or combination intervention for seven consecutive days. Psoriasis Area and Severity Index (PASI) scores were recorded daily. Histopathological analysis quantified epidermal thickness and dermal inflammatory cell infiltration. Serum and tissue levels of IL-23/IL-17-related inflammatory markers were measured by ELISA and qRT-PCR. The 60-min DPMF regimen demonstrated superior efficacy compared to 30-min exposure. The calcipotriol plus 60-min DPMF group achieved the lowest PASI score (2.50 ± 0.76) and exhibited the least epidermal hyperplasia and inflammatory cell infiltration. Furthermore, detection of IL-17, IL-22, and IL-23 levels in small samples of serum and tissue revealed that these indicators were nearly normalized following combined intervention. DPMF exposure was associated with downregulation of serum and tissue IL-23/IL-17-related inflammatory markers and improvement in psoriatic lesions, though direct mechanistic validation is required. Combining DPMF with calcipotriol produced enhanced therapeutic effects, providing preliminary experimental evidence for non-invasive physical intervention in psoriasis.
This systematic review and meta-analysis evaluated photobiomodulation (PBM) therapy for postoperative pain and secondary wound healing at the palatal donor site after connective tissue harvesting. Following PRISMA guidelines, five databases were searched through 20 October 2025 for randomized controlled trials comparing PBM therapy with appropriate controls. Primary outcomes were postoperative pain (visual analogue scale, VAS) and epithelialization; secondary outcomes were analgesic consumption, remaining wound area, and bleeding. Random-effects meta-analysis was used, risk of bias was assessed with the Cochrane Risk of Bias 2.0 tool and certainty of evidence with GRADE. Nine randomized controlled trials with 299 participants were included. Day-1 pain could not be pooled. No statistically significant difference in postoperative pain was observed at day 3 or day 7, with reductions of approximately 1.2 and 0.4 points on a 0–10 scale. Complete epithelialization at 14 days was more than twice as frequent, with no significant difference at day 21. The remaining wound area at day 7 was smaller by approximately 22 mm². Heterogeneity was moderate for pain and low for healing outcomes. PBM therapy may increase the proportion of palatal donor sites achieving complete epithelialization at 14 days. For postoperative pain the evidence is very uncertain, and no statistically significant reduction was observed at either pooled time point. Most trials carried a high or unclear risk of bias, and treatment protocols were heterogeneous. Larger trials with standardized dosimetry are needed to establish the clinical value of PBM therapy at the palatal donor site.
